TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias
Vandewiele F, Pironet A, Jacobs G, Kecskés M, Wegener J, Kerselaers S, Hendrikx L, Verelst J, Philippaert K, Oosterlinck W, Segal A, et al. (2022)
European Heart Journal 43(40): 4195-4207.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Vandewiele, Frone;
Pironet, Andy;
Jacobs, Griet;
Kecskés, Miklos;
Wegener, JörgUniBi ;
Kerselaers, Sara;
Hendrikx, Lio;
Verelst, Joren;
Philippaert, Koenraad;
Oosterlinck, Wouter;
Segal, Andrei;
Van Den Broeck, Evy
Alle
Alle
Abstract / Bemerkung
**Aims**
Cardiac arrhythmias are a major factor in the occurrence of morbidity and sudden death in patients with cardiovascular disease. Disturbances of Ca2+ homeostasis in the heart contribute to the initiation and maintenance of cardiac arrhythmias. Extrasystolic increases in intracellular Ca2+ lead to delayed afterdepolarizations and triggered activity, which can result in heart rhythm abnormalities. It is being suggested that the Ca2+-activated nonselective cation channel TRPM4 is involved in the aetiology of triggered activity, but the exact contribution and in vivo significance are still unclear. **Methods and results**
In vitro electrophysiological and calcium imaging technique as well as in vivo intracardiac and telemetric electrocardiogram measurements in physiological and pathophysiological conditions were performed. In two distinct Ca2+-dependent proarrhythmic models, freely moving Trpm4−/− mice displayed a reduced burden of cardiac arrhythmias. Looking further into the specific contribution of TRPM4 to the cellular mechanism of arrhythmias, TRPM4 was found to contribute to a long-lasting Ca2+ overload-induced background current, thereby regulating cell excitability in Ca2+ overload conditions. To expand these results, a compound screening revealed meclofenamate as a potent antagonist of TRPM4. In line with the findings from Trpm4−/− mice, 10 µM meclofenamate inhibited the Ca2+ overload-induced background current in ventricular cardiomyocytes and 15 mg/kg meclofenamate suppressed catecholaminergic polymorphic ventricular tachycardia-associated arrhythmias in a TRPM4-dependent manner. **Conclusion**
The presented data establish that TRPM4 represents a novel target in the prevention and treatment of Ca2+-dependent triggered arrhythmias.
Cardiac arrhythmias are a major factor in the occurrence of morbidity and sudden death in patients with cardiovascular disease. Disturbances of Ca2+ homeostasis in the heart contribute to the initiation and maintenance of cardiac arrhythmias. Extrasystolic increases in intracellular Ca2+ lead to delayed afterdepolarizations and triggered activity, which can result in heart rhythm abnormalities. It is being suggested that the Ca2+-activated nonselective cation channel TRPM4 is involved in the aetiology of triggered activity, but the exact contribution and in vivo significance are still unclear. **Methods and results**
In vitro electrophysiological and calcium imaging technique as well as in vivo intracardiac and telemetric electrocardiogram measurements in physiological and pathophysiological conditions were performed. In two distinct Ca2+-dependent proarrhythmic models, freely moving Trpm4−/− mice displayed a reduced burden of cardiac arrhythmias. Looking further into the specific contribution of TRPM4 to the cellular mechanism of arrhythmias, TRPM4 was found to contribute to a long-lasting Ca2+ overload-induced background current, thereby regulating cell excitability in Ca2+ overload conditions. To expand these results, a compound screening revealed meclofenamate as a potent antagonist of TRPM4. In line with the findings from Trpm4−/− mice, 10 µM meclofenamate inhibited the Ca2+ overload-induced background current in ventricular cardiomyocytes and 15 mg/kg meclofenamate suppressed catecholaminergic polymorphic ventricular tachycardia-associated arrhythmias in a TRPM4-dependent manner. **Conclusion**
The presented data establish that TRPM4 represents a novel target in the prevention and treatment of Ca2+-dependent triggered arrhythmias.
Erscheinungsjahr
2022
Zeitschriftentitel
European Heart Journal
Band
43
Ausgabe
40
Seite(n)
4195-4207
ISSN
0195-668X
eISSN
1522-9645
Page URI
https://pub.uni-bielefeld.de/record/2984471
Zitieren
Vandewiele F, Pironet A, Jacobs G, et al. TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. European Heart Journal. 2022;43(40):4195-4207.
Vandewiele, F., Pironet, A., Jacobs, G., Kecskés, M., Wegener, J., Kerselaers, S., Hendrikx, L., et al. (2022). TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. European Heart Journal, 43(40), 4195-4207. https://doi.org/10.1093/eurheartj/ehac354
Vandewiele, Frone, Pironet, Andy, Jacobs, Griet, Kecskés, Miklos, Wegener, Jörg, Kerselaers, Sara, Hendrikx, Lio, et al. 2022. “TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias”. European Heart Journal 43 (40): 4195-4207.
Vandewiele, F., Pironet, A., Jacobs, G., Kecskés, M., Wegener, J., Kerselaers, S., Hendrikx, L., Verelst, J., Philippaert, K., Oosterlinck, W., et al. (2022). TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. European Heart Journal 43, 4195-4207.
Vandewiele, F., et al., 2022. TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. European Heart Journal, 43(40), p 4195-4207.
F. Vandewiele, et al., “TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias”, European Heart Journal, vol. 43, 2022, pp. 4195-4207.
Vandewiele, F., Pironet, A., Jacobs, G., Kecskés, M., Wegener, J., Kerselaers, S., Hendrikx, L., Verelst, J., Philippaert, K., Oosterlinck, W., Segal, A., Van Den Broeck, E., Pinto, S., Priori, S.G., Lehnart, S.E., Nilius, B., Voets, T., Vennekens, R.: TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. European Heart Journal. 43, 4195-4207 (2022).
Vandewiele, Frone, Pironet, Andy, Jacobs, Griet, Kecskés, Miklos, Wegener, Jörg, Kerselaers, Sara, Hendrikx, Lio, Verelst, Joren, Philippaert, Koenraad, Oosterlinck, Wouter, Segal, Andrei, Van Den Broeck, Evy, Pinto, Silvia, Priori, Silvia G, Lehnart, Stephan E, Nilius, Bernd, Voets, Thomas, and Vennekens, Rudi. “TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias”. European Heart Journal 43.40 (2022): 4195-4207.